Last $99.58 USD
Change Today +0.07 / 0.07%
Volume 968.2K
BMRN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 01/27/15 All times are local (Market data is delayed by at least 15 minutes).

biomarin pharmaceutical inc (BMRN) Snapshot

Open
$99.00
Previous Close
$99.51
Day High
$100.43
Day Low
$98.01
52 Week High
01/15/15 - $100.50
52 Week Low
04/15/14 - $55.04
Market Cap
15.7B
Average Volume 10 Days
1.7M
EPS TTM
$-1.15
Shares Outstanding
157.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOMARIN PHARMACEUTICAL INC (BMRN)

biomarin pharmaceutical inc (BMRN) Details

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme for the treatment of mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), a metabolic disease; Aldurazyme used for the treatment of mucopolysaccharidosis I, a genetic disease; Firdapse used to treat Lambert Eaton Myasthenic Syndrome, an autoimmune disease; and Vimizim, an enzyme replacement therapy to treat MPS IVA, a lysosomal storage disorder. The company also develops PEG-PAL, an enzyme substitution therapy that is under Phase III clinical trial to treat PKU; BMN-701, an enzyme replacement therapy, which is under Phase I/II clinical trial for Pompe disease, a glycogen storage disorder; BMN-673, a poly ADP-ribose polymerase inhibitor that is in Phase III clinical trial to treat germline BRCA breast cancer; and BMN-111, a C-natriuretic peptide that is under Phase I clinical trial to treat achondroplasia. In addition, it develops BMN 190, a recombinant human tripeptidyl peptidase-1 in Phase 1 clinical trial to treat late-infantile neuronal ceroid lipofuscinosis, a form of Batten Disease; BMN 270, an AAV-factor VIII vector to treat hemophilia A; and BMN 250, a novel fusion of alpha-N-acetyglucosaminidase to treat MPS IIIB. The company sells its Naglazyme, Kuvan, and Firdapse products to specialty pharmacies and end-users, such as hospitals and foreign government agencies, which act as retailers; and Naglazyme products to distributors and pharmaceutical wholesalers. It has a collaboration agreement with Genzyme Corporation; and an agreement with Merck Serono S.A. BioMarin Pharmaceutical Inc. was founded in 1996 and is headquartered in San Rafael, California.

1,341 Employees
Last Reported Date: 02/26/14
Founded in 1996

biomarin pharmaceutical inc (BMRN) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $868.8K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $457.8K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $631.9K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $409.6K
Executive Vice President of Technical Operati...
Total Annual Compensation: $414.4K
Compensation as of Fiscal Year 2013.

biomarin pharmaceutical inc (BMRN) Key Developments

BioMarin Pharmaceutical Inc. Provides Preliminary Data from Ongoing Phase 1/2 Pivotal Study of BMN 190 for Treatment of CLN2 Disorder

BioMarin Pharmaceutical Inc. announced interim results from its Phase 1/2 pivotal study for BMN 190 or cerliponase alfa, a recombinant human tripeptidyl peptidase 1 (rhTPP1), to treat of patients with late infantile CLN2 disease, a form of Batten disease. Interim data indicates that in all nine of the BMN 190 patients who have been followed for at least six months and up to 15 months, the treatment appears to show stabilization of the disease compared to the natural history based on a standardized measure of motor and language function. The primary end point of the study is a standardized mobility and language score using a CLN2-specific rating scale. The scale separately measures performance of mobility and language with normal function in each being a score of three and no function being a score of zero. The higher score possible is six. According to data from a natural history study of the disease, patients generally lose one point every six months and generally lose most language and mobility functioning over a two to four year period in this rapidly progressive disease. In the nine BMN 190 patients treated for more than six months and up to 15 months, six patients showed no net change in their CLN2 rating scale score, while the other three showed a decline of one point. In addition, seven of the nine patients in the BMN 190 study for more than six months were matched to between one and 12 individuals from the natural history data set according to baseline age and disease severity. (For two of the BMN 190 patients, there is no matched patient in the natural history database based on age and disease severity.) All seven BMN 190 patients with six months of treatment and at least one control match had better walk/talk scores as of their last evaluation than their natural history counterparts. There is no approved treatment that can prevent, stop, or reverse CLN2 disorder. Palliative care to reduce seizures and physical rehabilitative care to help children retain muscle function for as long as possible are currently the available treatment options for patients with this rare disease. The Phase 1/2 pivotal study is an open-label, dose-escalation study in patients with late infantile CLN2 disease, a form of Batten disease. The primary objectives are to evaluate the safety and tolerability of BMN 190 or cerliponase alfa and to evaluate effectiveness using a CLN2 disorder-specific rating scale score in comparison with natural history data after 48 weeks of treatment. Secondary objectives are to evaluate the impact of treatment on brain atrophy in comparison with CLN2 natural history after 48 weeks of treatment and to characterize pharmacokinetics and immunogenicity. The study enrolled 24 subjects at five clinical sites for a planned treatment duration of 48 weeks. Complete results are expected in the fourth quarter of 2015.

BioMarin Pharmaceutical Inc. Announces Executive Changes

BioMarin Pharmaceutical Inc. announced that Pierre Lapalme has elected to step down as Chairman of the company's Board of Directors following the annual meeting of stockholders anticipated in June 2015. Mr. Lapalme will seek re-election to serve as a Director on BioMarin's Board at the meeting. Following Mr. Lapalme's decision, the Board elected to revise the organizational structure of the Board and the company. The Board created the position of Lead Independent Director to serve as a liaison between the Chief Executive Officer and the independent directors, and to facilitate discussions and deliberation among the independent directors in fulfilling their oversight responsibilities for the company. The Board has determined that Richard Meier will serve as the Lead Independent Director effective on Mr. Lapalme stepping down as Chairman. Also effective on Mr. Lapalme stepping down as Chairman, to better align the operational leadership of the company, the Board has determined Jean-Jacques Bienaim, Chief Executive Officer of BioMarin, will assume the role of Chairman of the Board.

BioMarin Pharmaceutical Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 10:30 AM

BioMarin Pharmaceutical Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 10:30 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Jean-Jacques Bienaimé, Chief Executive Officer and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BMRN:US $99.58 USD +0.07

BMRN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actelion Ltd SFr.100.60 CHF -0.10
Alkermes PLC $70.55 USD -0.81
Jazz Pharmaceuticals PLC $174.53 USD -2.25
Spectrum Pharmaceuticals Inc $6.93 USD +0.02
Vertex Pharmaceuticals Inc $123.67 USD -1.45
View Industry Companies
 

Industry Analysis

BMRN

Industry Average

Valuation BMRN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 21.9x
Price/Book 9.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 21.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOMARIN PHARMACEUTICAL INC, please visit www.biomarinpharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.